Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

✍ Scribed by Liao, Cheng; Hsu, Jonathan; Kim, Yong; Hu, Dong-Qing; Xu, Daigen; Zhang, Jun; Pashine, Achal; Menke, John; Whittard, Toni; Romero, Natasha; Truitt, Theresa; Slade, Michelle; Lukacs, Christine; Hermann, Johannes; Zhou, Mingyan; Lucas, Matthew; Narula, Satwant; DeMartino, Julie; Tan, Seng-Lai

• Book ID: 121605857
• Publisher: BioMed Central
• Year: 2013
• Tongue: English
• Weight: 893 KB
• Volume: 15
• Category: Article
• ISSN: 1478-6354
• DOI: 10.1186/ar4329